Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 25
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
G Chir ; 39(1): 57-62, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29549683

RESUMEN

BACKGROUND: Retroperitoneal or mesenteric primary liposarcoma is a malignant neoplasia whose prognosis depends on the biological variants, the radical resection surgery and the histological subtypes, as well as on local and remote recurrences. Liposarcoma is the most common variant of this tumour among tumours of soft retroperitoneal tissue. The purpose of this study is to evaluate whether the treatment of this disease, carried out at the Ivrea Hospital for urgent reasons, may be considered in line with the experience of high-volume Centres. PATIENTS AND METHODS: Between 1982 and 2016 five patients were hospitalized with a diagnosis of acute abdomen due to retroperitoneal or mesenteric primary liposarcoma: one myxoid of the mesentery, one well-differentiated of lesser epiploon, one well-differentiated of mesentery, and two dedifferentiates of the retroperitoneum. RESULTS: The five patients, all males, had a average age of 59 years (range 48-86) and were all subjected to general anaesthesia and open technique for total tumour removal. Only the patient with the myxoid liposarcoma had two recurrences. All are alive and healthy after a follow-up of 177 months (range 9-420). CONCLUSION: These tumours should be removed radically, if necessary in conjunction with contiguous organs. Rarity and therapeutic complexity require a treatment, sometimes even multimodal, in highvolume centres. Patients admitted in General Surgery Unit for unpostponable urgency should be operated by surgeons experienced in the treatment of abdominal disease to achieve survival results in line to those achievable in Hub Centres.


Asunto(s)
Liposarcoma/patología , Mesenterio/patología , Neoplasias Peritoneales/patología , Neoplasias Retroperitoneales/patología , Abdomen Agudo/etiología , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Quimioterapia Adyuvante , Terapia Combinada , Epirrubicina/administración & dosificación , Estudios de Seguimiento , Humanos , Ifosfamida/administración & dosificación , Leiomiosarcoma/patología , Leiomiosarcoma/cirugía , Liposarcoma/diagnóstico por imagen , Liposarcoma/tratamiento farmacológico , Liposarcoma/cirugía , Liposarcoma Mixoide/tratamiento farmacológico , Liposarcoma Mixoide/patología , Liposarcoma Mixoide/cirugía , Masculino , Mesenterio/diagnóstico por imagen , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Neoplasias Primarias Secundarias/patología , Neoplasias Primarias Secundarias/cirugía , Neoplasias Peritoneales/diagnóstico por imagen , Neoplasias Peritoneales/cirugía , Pronóstico , Neoplasias Retroperitoneales/diagnóstico por imagen , Neoplasias Retroperitoneales/tratamiento farmacológico , Neoplasias Retroperitoneales/cirugía
2.
J Endocrinol Invest ; 39(8): 939-53, 2016 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-27059212

RESUMEN

PURPOSE: The diagnostic, therapeutic and health-care management protocol (Protocollo Gestionale Diagnostico-Terapeutico-Assistenziale, PDTA) by the Association of the Italian Endocrine Surgery Units (U.E.C. CLUB) aims to help treat the patient in a topical, rational way that can be shared by health-care professionals. METHODS: This fourth consensus conference involved: a selected group of experts in the preliminary phase; all members, via e-mail, in the elaboration phase; all the participants of the XI National Congress of the U.E.C. CLUB held in Naples in the final phase. The following were examined: diagnostic pathway and clinical evaluation; mode of admission and waiting time; therapeutic pathway (patient preparation for surgery, surgical treatment, postoperative management, management of major complications); hospital discharge and patient information; outpatient care and follow-up. RESULTS: A clear and concise style was adopted to illustrate the reasons and scientific rationales behind behaviors and to provide health-care professionals with a guide as complete as possible on who, when, how and why to act. The protocol is meant to help the surgeon to treat the patient in a topical, rational way that can be shared by health-care professionals, but without influencing in any way the physician-patient relationship, which is based on trust and clinical judgment in each individual case. CONCLUSIONS: The PDTA in thyroid surgery approved by the fourth consensus conference (June 2015) is the official PDTA of U.E.C. CLUB.


Asunto(s)
Atención a la Salud/normas , Hospitalización/estadística & datos numéricos , Guías de Práctica Clínica como Asunto/normas , Enfermedades de la Tiroides/diagnóstico , Enfermedades de la Tiroides/cirugía , Tiroidectomía/normas , Tiempo de Tratamiento/normas , Consenso , Humanos , Italia
3.
Minerva Chir ; 67(3): 271-5, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22691831

RESUMEN

Thyroidectomy is one of the commonest surgical operations performed in endocrine surgery; results are generally excellent and morbidity and mortality usually are negligible. Total thyroidectomy's complication rates are low, with an overall incidence of 4.3% among experienced surgeons: the most frequent complications are vocal cord paresis or paralysis, hypoparathyroidism, hypocalcemia, haematoma and wound infection. Tracheal injury following thyroidectomy is even more rare. As reported from some authors, inadvertent tracheal injury has an incidence of 0-0.6% during thyroidectomy. Tracheal laceration (generally located in the posterolateral surface) is often recognized and repaired immediately, during the same intervention. Rarely, following a total thyroidectomy, a delayed tracheal rupture may occur secondary to an ischemic damage of the trachea. This has been described in few cases reported in literature. In this paper we report of a case in which delayed tracheal lacerations appeared 10 days after the patient underwent total thyroidectomy: a prompt surgical operation was efficient using both direct sutures of tracheal breaches and a patch of fibrinogen-thrombin coated collagen fleece covering the entire surface.


Asunto(s)
Fibrinógeno , Isquemia/complicaciones , Laceraciones/etiología , Laceraciones/terapia , Tapones Quirúrgicos de Gaza , Trombina , Tiroidectomía/efectos adversos , Tráquea/irrigación sanguínea , Tráquea/lesiones , Adulto , Combinación de Medicamentos , Humanos , Masculino , Necrosis , Tiroidectomía/métodos , Factores de Tiempo , Tráquea/patología
4.
G Chir ; 32(6-7): 316-9, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21771399

RESUMEN

INTRODUCTION: Anomalies of the gallbladder position in the biliary tract are rare, but they could be very dangerous during cholecystectomy. CASE REPORT: A 48-year-old man presented with a 2-week history of intermittent epigastric pain, scleral jaundice and elevation of liver function tests. After a magnetic resonance cholangiogram and an endoscopic retrograde cholangiogram with sphincterotomy, he was submitted to laparoscopic cholecystectomy, the conversion to laparotomy was decided for the suspect of gallbladder interposition. The anatomical anomaly was confirmed and a Roux-en-Y hepaticojejunostomy was executed, with end-to-side anastomosis between the confluence of the hepatic ducts and the fourth loop of jejunum, on a biliary stent. This catheter was removed in the tenth postoperative day; after cholangiography and CT abdominal scan the patient was discharged, without complications. CONCLUSION: The gallbladder interposition is a rare malformation which seems to arise from an embryonic anomaly occurring between the 4th and the 5th week and whose potential causes have not been detected. A similar outcome could be also determined by a Mirizzi syndrome, but in our case it is excluded because intra-operatively there was no inflammatory reaction that could justify the presence of a fistula between the gallbladder and the common hepatic duct. Once the gallbladder interposition is found, the surgical treatment consists in removing the gallbladder itself and the corresponding part of the common hepatic duct. The reconstruction is carried out by a Roux-en-Y hepaticojejunostomy with anastomosis at the hepatic hilum, positioning a biliary stent.


Asunto(s)
Anomalías Múltiples , Vesícula Biliar/anomalías , Conducto Hepático Común/anomalías , Anomalías Múltiples/diagnóstico , Anomalías Múltiples/cirugía , Humanos , Masculino , Persona de Mediana Edad
5.
G Chir ; 28(1-2): 20-4, 2007.
Artículo en Italiano | MEDLINE | ID: mdl-17313728

RESUMEN

Desmoid tumors are rare benign neoplasms with high tendency to local recurrence, and they can be divided into extra- and intra-abdominal types (mesenteric fibromatosis). Eight cases have been treated in our Department from 1997 to 2006. Six patients (3 men and 3 women) affected by extra-abdominal desmoid tumors have been treated with radical excision. In two patients desmoid was intra-abdominal: 1) a 55 years old man admitted for acute abdomen and submitted, in emergency, to a laparotomy with excision of a mesenteric abscess including a jejunal loop at about one meter from Treitz; 2) 52 years old man, submitted to an elective excision of a capsulated neoplasm of the little omentum, which had caused an oppressive abdominal pain. In both cases the hystological diagnosis has been desmoid tumor. Surgical treatment of desmoid tumors must aim at radical excision to avoid frequent recurrences (25-65%); these have stimulated the research of other kinds of treatments, since a new surgical operation itself can lead to a further recurrence. Radiotherapy has been investigated with results in 79-96% of cases, antiestrogenic therapy has been used with success in 51% of patients, and high dose tamoxifen seemed to obtain a stable disease in non operable cases. Non steroidal anti-inflammatory drugs have been experimented in association with tamoxifen and chemotherapy. Conclusive results on the efficacy of these treatments have not been obtained yet, because of the rarity of the desmoid tumors even in greater Centres.


Asunto(s)
Fibromatosis Abdominal/cirugía , Mesenterio , Neoplasias Peritoneales/cirugía , Neoplasias Abdominales/patología , Neoplasias Abdominales/cirugía , Anciano , Femenino , Fibromatosis Abdominal/patología , Fibromatosis Agresiva/cirugía , Humanos , Masculino , Persona de Mediana Edad , Neoplasias Peritoneales/patología , Estudios Retrospectivos , Resultado del Tratamiento
6.
G Chir ; 28(4): 149-52, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17475117

RESUMEN

Unilateral phrenic nerve paralysis is a rare complication of cervico-mediastinal goitre. It occurs when adhesions grow between the intrathoracic part of the thyroid and the nerve, specially where the goitre enters the mediastinum behind the first rib. The damage may be caused by strain of the nerve due to the descent of the goitre into the chest or may be caused by the surgical manoeuvres during thyroidectomy performed by cervical approach. Two patients operated on for large cervico-mediastinal goitre are reported: a 70-year-old male with a large intrathoracic growth of the left thyroid lobe and a 54-year-old male with a large intrathoracic growth to the right lobe. A few days after total thyroidectomy they showed signs of exertional dyspnoea. The exams performed showed hemi-diaphragm relaxatio due to phrenic nerve paralysis, with resulting reduction of respiratory space. Phrenic nerve paralysis may follow total thyroidectomy for large cervico-mediastinal goitres; is not due to the operative technique, but rather to the particular anatomic conditions which may be found.


Asunto(s)
Bocio/cirugía , Parálisis/etiología , Enfermedades del Sistema Nervioso Periférico/etiología , Nervio Frénico , Tiroidectomía/efectos adversos , Anciano , Bocio/patología , Humanos , Masculino , Persona de Mediana Edad , Tiroidectomía/métodos
7.
G Chir ; 27(5): 199-204, 2006 May.
Artículo en Italiano | MEDLINE | ID: mdl-16857108

RESUMEN

We studied the incidence of anastomotic leakage in colorectal surgery with the alternative use of stapled anastomosis, hand sewn anastomosis and stapled/hand sewn anastomosis. 477 consecutive patients admitted for elective or emergency colon surgery were divided in: Group I? 337 elective patients submitted to mechanical bowel preparation; Group II - 140 emergency patients operated without mechanical bowel preparation. We analyzed surgical complications in the two group considering the different anastomosis made (stapled, hand sewn and stapled/hand sewn). Anastomotic leakages were 11 (3.3%) in Group I: 7 in stapled (3,4%), 2 in hand sewn (2,1%) and 2 in stapled/hand sewn anastomosis (5,3%); 10 patients (91%) with peritonitis or intra-abdominal abscess required re-intervention and there was a correlated death. In Group II there were 6 anastomotic leakages (4,2%): 1 in stapled (1,4%), 3 in hand sewn (8,3%) and 2 in stapled/hand sewn anastomosis (5,7%); four patients required re-intervention and there were no correlated deaths. Mean postoperative stays were similar among the different techniques of suture in the two groups. No statistically significant differences in surgical complications were noted among stapled, hand sewn and stapled/hand sewn anastomosis. The choice should be based on personal preference and surgeon experience, considering costs, using hand sewn suture whenever is possible.


Asunto(s)
Anastomosis Quirúrgica/métodos , Cirugía Colorrectal/métodos , Absceso Abdominal/cirugía , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Anastomosis Quirúrgica/efectos adversos , Neoplasias del Colon/cirugía , Interpretación Estadística de Datos , Diverticulosis del Colon/cirugía , Urgencias Médicas , Femenino , Humanos , Enfermedades Inflamatorias del Intestino/cirugía , Masculino , Persona de Mediana Edad , Peritonitis/cirugía , Neoplasias del Recto/cirugía , Reoperación , Factores de Riesgo , Factores Sexuales , Engrapadoras Quirúrgicas , Técnicas de Sutura
8.
Cancer Chemother Pharmacol ; 35(4): 339-42, 1995.
Artículo en Inglés | MEDLINE | ID: mdl-7828278

RESUMEN

A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i.v. bolus for 5 consecutive days, preceded by a rapid i.v. bolus of 200 mg/m2 5-methyltetrahydrofolic acid. The treatment was repeated every 4 weeks. The median age of the patients was 68 years and their median Eastern Cooperative Oncology Group (ECOG) performance status was 1. There were 7 patients with locally advanced disease and 13 with distant metastases (median, 2 sites). A median of 3 monthly cycles of treatment (range, 1-7) were given, with a corresponding dose intensity of 396 mg/m2 per week (86% of that planned). No complete response, 1 partial response, and 8 cases of disease stabilization were obtained. In general the regimen was well tolerated, with only 2 patients suffering from grade 3 stomatitis or diarrhea; the most common toxicity was nausea, which was experienced by almost 50% of the patients. The combination of 5-methyltetrahydrofolate plus 5-fluorouracil appears as little effective in this disease as 5-fluorouracil plus 5-formyltetrahydrofolate (leucovorin). It is suggested that bolus 5-fluorouracil is so inactive as an "effector agent" against pancreatic cancer that its biochemical modulation with exogenous high-dose reduced folates cannot improve the therapeutic outcome produced by the fluoropyrimidine in these patients.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Pancreáticas/tratamiento farmacológico , Adenocarcinoma/tratamiento farmacológico , Adulto , Anciano , Femenino , Fluorouracilo/administración & dosificación , Humanos , Italia , Masculino , Persona de Mediana Edad , Inducción de Remisión , Tetrahidrofolatos/administración & dosificación
9.
Anticancer Res ; 16(2): 937-41, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8687155

RESUMEN

Transcatheter chemoembolization, in conjunction with various drugs, has been widely used for palliative treatment of hepatocellular carcinoma. A phase II study was carried out on mitoxantrone chemoembolization. High risk cirrhotic patients were excluded from this study. Fourteen mg/m2 mitoxantrone and up to 20 ml Lipiodol were injected, followed by Gelfoam embolization as indicated. Thirty-seven patients (33 with cirrhosis) were treated. Sixty-nine cycles were delivered, with mean (+/-SD) Lipiodol and emulsified mitoxantrone doses of 11.3+/-3.8 ml and 11.8+/-5.2 mg, respectively. Thirteen, 16, and 8 patients received one, two, and three cycles, respectively, with time intervals of 123+/-60 days. Thirty patients received Gelfoam embolization at the first cycle, 9 at the second and 4 at the third. No treatment-related deaths occurred. Complications were mild and transient, including nausea/vomiting in most cases, fever over 38 degrees C 67%, pain 74%, ascites 8%, jaundice 3%, bleeding 3%, pancreatitis 3%, myelosuppression 44%, diarrhea 5%. Treatment response rate was 49% (including 16% minor responses) with 16% early progressions. With a median follow-up of 12 months, the 12-month response duration and survival rates were 56% and 79% respectively. Transcatheter chemoembolization with mitoxantrone appears to be a promising method for the palliation of advanced hepatocellular carcinoma, and deserves to be evaluated in well controlled randomized studies.


Asunto(s)
Antineoplásicos/administración & dosificación , Carcinoma Hepatocelular/terapia , Quimioembolización Terapéutica , Esponja de Gelatina Absorbible/administración & dosificación , Hemostáticos/administración & dosificación , Aceite Yodado/administración & dosificación , Neoplasias Hepáticas/terapia , Mitoxantrona/administración & dosificación , Femenino , Humanos , Masculino , Cuidados Paliativos , Proyectos Piloto
10.
Anticancer Res ; 17(1B): 787-90, 1997.
Artículo en Inglés | MEDLINE | ID: mdl-9066621

RESUMEN

The influence of the timing of surgery in relation to the menstrual cycle on the survival of breast cancer patients has been both advocated and disputed. The records of 165 premenopausal M- breast cancer women consecutively operated from 1977 to 1991 were reviewed. All patients underwent modified radical mastectomies or quadrantectomies plus postoperative radiotherapy. Node-positive patients received adjuvant chemotherapy. Cox regression analysis was used to estimate the relative risk (RR) of death in three models including timing of surgery, age, histology, pT and pN. In each model, patients were divided into two groups according to the criteria proposed by Badwe, Hrushesky, and Senie. Multivariate analysis showed a significant association between pT and pN and survival, whereas no association with survival was observed for the timing of surgery according to either Badwe or Hrushesky or Senie (RR = 1.26, RR = 0.91 and RR = 0.88 respectively). Consensus on the menstrual phase related to the expected best prognosis is still required.


Asunto(s)
Neoplasias de la Mama/fisiopatología , Neoplasias de la Mama/cirugía , Ciclo Menstrual/fisiología , Premenopausia/fisiología , Adulto , Neoplasias de la Mama/patología , Femenino , Humanos , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Estudios Retrospectivos , Factores de Tiempo
11.
Anticancer Res ; 16(4A): 2017-24, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8712736

RESUMEN

Hyperthermic Antiblastic Perfusion (HAP) is a widely used method for the treatment of recurrent limb melanoma. In terms of tumor response, locoregional control and survival HAP has led to better results than those achieved with any other treatment. The aim of this report is to analyze our own experience with HAP in locally advanced limb melanoma. Thirty-two patients were submitted to HAP. HAP lasted 60 minutes, with maximal local temperature of 40.5-42 degrees C using melphalan 10 mg/L limb volume as antiblastic agent. Twenty patients had in-transit metastases and 12 local recurrence. Regional nodes were involved in 12 patients. Systemic leakage monitored with 125I or 99Tc ranged between 5-30% (mean 14%). No operative mortality nor major complications occurred. Local toxicity scored Wieberdink grade I in 8 patients, grade II in 17, grade III in 6 and grade IV in 1 case. Response rate (UICC) in the 16 patients treated with unexcised lesions was 94% (56% complete responses). With a median follow-up of 29 months (2-126) 14 patients relapsed after a median time of 10 months, and 17 patients are currently disease free, 3 of these are being reexcised and 3 re-perfused. Actuarial 5 years survival was 64%, with 39% disease free to the first relapse. Our results are consistent with the literature indicating HAP as a safe procedure with a high evidence of clinical responses.


Asunto(s)
Antineoplásicos Alquilantes/uso terapéutico , Hipertermia Inducida , Melanoma/terapia , Melfalán/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos Alquilantes/administración & dosificación , Terapia Combinada , Supervivencia sin Enfermedad , Circulación Extracorporea , Femenino , Humanos , Hipertermia Inducida/efectos adversos , Hipertermia Inducida/métodos , Hipertermia Inducida/mortalidad , Pierna , Masculino , Melanoma/mortalidad , Melanoma/patología , Melfalán/administración & dosificación , Persona de Mediana Edad , Metástasis de la Neoplasia , Recurrencia , Tasa de Supervivencia , Factores de Tiempo
12.
Minerva Cardioangiol ; 42(5): 245-8, 1994 May.
Artículo en Italiano | MEDLINE | ID: mdl-8090297

RESUMEN

Tobacco use represents the most powerful chemical addiction, which has been defined as "the inability to discontinue smoking" and it is one of the main cardiovascular risk factors. It produces alterations in platelet activity, blood viscosity and vascular wall and clinical signs related to the different vascular districts. The probability of carotid lesions increases up to 32% for 10 years/smoking and the progression of the disease is proportional to tobacco consumption; on the contrary smoking cessation may be helpful. Furthermore the risk of PAOD increases 2 to 9-fold, irrespective the number of cigarettes and these modify significantly the long-term patency of the femoro-distal reconstructions (57% vs 78% at 2 years). Very impressive indeed the data concerning major amputations (21% vs 2%) and the mortality rate for cardiovascular diseases (83% vs 33%) between smokers and non-smokers. For the abdominal aortic aneurysm too smoking represents the main independent risk factor and the mortality rate rises 6 to 25-fold compared to the normal population. The conclusions are obvious and can be shortly summarized in the following sentence: "Stop smoking and keep walking".


Asunto(s)
Enfermedades Cardiovasculares/etiología , Fumar/efectos adversos , Adulto , Anciano , Amputación Quirúrgica , Aneurisma de la Aorta Abdominal/etiología , Aneurisma de la Aorta Abdominal/mortalidad , Aneurisma de la Aorta Abdominal/prevención & control , Enfermedades Cardiovasculares/mortalidad , Enfermedades Cardiovasculares/prevención & control , Enfermedad Coronaria/etiología , Enfermedad Coronaria/mortalidad , Enfermedad Coronaria/prevención & control , Ejercicio Físico , Femenino , Humanos , Pierna/irrigación sanguínea , Pierna/cirugía , Masculino , Persona de Mediana Edad , Factores de Riesgo , Cese del Hábito de Fumar , Tromboflebitis/etiología , Tromboflebitis/prevención & control , Tromboflebitis/cirugía
13.
Clin Drug Investig ; 12(2): 94-104, 1996 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24610670

RESUMEN

A pharmacokinetic study was carried out in patients with unresectable colorectal liver metastases who had primarily been included in a phase II trial of intra-arterial cisplatin (DDP) plus intravenous fluorouracil. Ten patients of those accrued for the clinical study underwent the pharmacokinetic investigation upon liver progression of the disease. Four patients were treated with DDP (24 mg/m(2)) through short intra-arterial infusion (baseline study) and 4 patients received intra-arterial hyaluronidase (HY, 100 000IU) 2 minutes before DDP infusion. Two additional patients were treated with both DDP alone and DDP + HY. Plasma concentrations of total and free platinum (Pt) were consistently lower than baseline in the presence of HY. HY administration resulted in a longer terminal half-life (2.1 ± 0.7 vs 1.0 ± 0.2 days, p < 0.05), a reduced area under the plasma concentration-time curve from 0 to 2 hours (AUC0-2h) [0.08 ± 0.009 vs 0.12 ± 0.017 g/L•min, p < 0.01], and an increased volume of distribution, both initially (11.7 ± 3.4 vs 6.6 ± 2.1L, p < 0.05) and at steady-state (43.0 ± 10.8 vs 22.1 ± 8.8L, p < 0.05), for total Pt. However, significant HY-related effects on the overall plasma exposure (AUC0-∞) to total Pt or on the total body clearance were not observed. HY treatment was also associated with a lower plasma concentration at time zero (C0) [p < 0.01 ] and AUC0-2h (p < 0.02), and a higher plasma clearance (p < 0.02) and apparent volume of distribution (p < 0.05), for free Pt. Renal clearance (CLR) and cumulative urinary excretion of Pt were significantly increased (p < 0.01) by HY, while fluid output was not significantly affected. The increase in both CLR and the extent of Pt distribution was not due to a protein binding drug interaction nor to a reaction between DDP and HY in the plasma. Combined treatment with HY yielded a clinically acceptable toxicity.

14.
Minerva Chir ; 55(10): 693-702, 2000 Oct.
Artículo en Italiano | MEDLINE | ID: mdl-11236346

RESUMEN

BACKGROUND: Thyroid surgery presents a low incidence of complications. Death is certainly a rare, or even exceptional event. Hypoparathyroidism, above all if definitive, is the main complication of total thyroidectomy with percentages that very between 0 and 10% in the literature (average 2%). METHODS: The incidence of recurrent lesions varies between an improbable 0% to 8%, whereas lesions to the superior laryngeal nerve are relatively frequent, but often undervalued. Dysphagia, although always transient, presents a high risk of pneumonia ab ingestis and severe dehydration. Hemorrhage has an incidence of 0.1-3.8% and infection is reported in approximately 1% of cases. The permanent and recurrence nature of thyroid pathology in literature is between 5 and 11%, resulting from inadequate or sometimes useless surgery. Hypothyroidism is the logical consequence of total thyroidectomy. In the light of these data we have re-examined 300 operations involving thyroid pathology performed by the same team using the same method over the past 4 years (82% females, 18% males). 33% of the cases presented benign euthyroid nodular pathology, 27% hyperfunctioning benign nodular pathology, 2.6% Flajani-Basedow-Graves disease, 9% were adenomas, 7% were differentiated carcinomas, 2% anaplastic carcinomas and 0.7% medullary carcinomas. 99 extracapsular total loboisthmectomies, 135 total extracapsular thyroidectomies and 66 subtotal thyroidectomies were performed. RESULTS: The following complications were observed: 31/300 symptomatic hypocalcemias of which 25 were transient and 6 (2%) were definitive but easily controlled with treatment; 9 recurrent monoplegias out of 501 isolated recurrent forms of which 4 (0.8%) was permanent; 5/300 (1.7%) postoperative dysphagias associated with recurrent monoplegia in 4 cases. Damage to the external branch of the superior laryngeal nerve was suspected in 11/300 cases (3.7%). Postoperative hemorrhage occurred with an incidence of 1.3%, whereas the incidence of wound infection and serous collection was 1.7%. Moreover, persistent hyperthyroidism after subtotal bilateral thyroidectomy was observed secondary to toxic plurinodular struma. A case of paralysis of the right ulnar nerve, when the arm was adducted, was observed on the operating table, but regressed after about 4 months. Mortality was zero. CONCLUSIONS: Thyroid surgery is still hampered by a relatively low percentage of complications, which are probably still the result of various technical limitations, and it appears difficult to reduce these, let alone eliminate them completely.


Asunto(s)
Complicaciones Posoperatorias/epidemiología , Enfermedades de la Tiroides/cirugía , Adolescente , Adulto , Anciano , Femenino , Humanos , Incidencia , Masculino , Persona de Mediana Edad
15.
Minerva Chir ; 49(6): 539-51, 1994 Jun.
Artículo en Italiano | MEDLINE | ID: mdl-7970058

RESUMEN

Since January 1992 a feasibility study was set up to establish the possible role of pelvic hyperthermochemotherapy for the local control of rectal cancer. Patients with resectable rectal cancer (clinical stage III-IV) are eligible for the study. Only patients submitted to abdominoperineal resection with or without extended pelvic linfoadenectomy (PLND) and/or resection of contiguous organs are included in the initial pilot phase of the study. Until now, two patients with stage III rectal cancer submitted to abdominoperineal resection and PLND have been treated. A single (40 mg) push of MMC was injected in the circuit with median local temperature of 46.0 +/- 0.3 and 45.9 +/- 0.5 degrees C and the pelvis was perfused for 60 min. There were no local or systemic complications. The ratio between the pelvis and plasma AUCs showed a high local pharmacokinetic advantage. The treatment can contribute to complete the standard protocols of adjuvant therapy. Since the simple decrease of local recurrence could represent an important clinical aim, this experience, even initial, supports us to continue the study.


Asunto(s)
Hipertermia Inducida , Neoplasias del Recto/terapia , Anciano , Terapia Combinada , Estudios de Factibilidad , Femenino , Humanos , Hipertermia Inducida/instrumentación , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Neoplasias del Recto/patología
16.
Minerva Chir ; 51(6): 405-12, 1996 Jun.
Artículo en Italiano | MEDLINE | ID: mdl-8992387

RESUMEN

Between January, 1991 and December, 1993, 208 subjects with monolateral and 19 with bilateral inguinal hernia were submitted to herniorrhaphy. Thirty-four were recurrent hernias. All but one bilateral hernias were treated at the same time. Eight cases were operated in emergency condition for acute strangulated hernia. Two-hundred and ten operations were performed under local, 17 under general and 1 under spinal anesthesia. Herniorrhaphy was performed in 14 cases with the Bassini and in 38 with the Shouldice technique. In 191 instances the "tension-free" and in 3 the "plug" techniques were adopted utilizing a polypropylene mesh. Following local anesthesia 13 episodes of bradycardia with hypotension were recorded during the operation and 4 in the early postop period. There were no general complications. Two elderly patients developed urinary retention following general anesthesia. Local complications included 6 (2.4%) cases of infection and 4 (1.6%) cases of hematoma of the wound, and 5 (2.0%) cases of edema with infiltration of the cord. Percentage of follow-up at 1, 2 and 3 years was 96, 95, and 93 percent respectively. Five recurrences were recorded: in 1 case following Bassini repair (7.6%), in 2 following Shouldice (5.6%), and in 2 following tension-free (1.5%). Local anesthesia has been confirmed to be well accepted by the patients, effective an safe, especially in the elderly patients with high operative risk. Similarly, the tension-free hernioplasty has been confirmed as a simple, easily reproducible technique, followed by less pain and disability as compared with other types of herniorrhaphies, and more effective mainly in the treatment of recurrent hernia.


Asunto(s)
Anestesia Local , Hernia Inguinal/cirugía , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Procedimientos Quirúrgicos Operativos/métodos
17.
Minerva Chir ; 49(7-8): 681-91, 1994.
Artículo en Italiano | MEDLINE | ID: mdl-7991176

RESUMEN

Twenty-two patients with recurrent melanoma of the limbs, underwent Hyperthermic Antiblastic Perfusion (HAP). HAP lasted 60 min, with maximal local temperature of 40.5-42 degrees C and melphalan 10 mg/L limb volume as antiblastic agent. Fourteen patients had in-transit metastases and 8 local recurrences. Regional nodes were involved in 6 patients. Systemic leakage monitored with 125I or 99Tc ranged between 5 and 30% (mean 19%). No operative mortality nor major complications occurred. Local toxicity scored Wieberdink grade I in 6 patients, grade II in 11 and III in 5. Response rate (UICC) in the 9 patients treated with unexcised lesions was 88% (55% complete responses). After a median follow-up of 27 months (1-92) 9 patients relapsed after a median time of 17 months, and 15 patients are currently disease free, 4 of them being re-excised and one reperfused. Actuarial 5 year survival is 67%, with 45% disease free to the first relapse. Our results are consistent with the literature indicating HAP as a safe procedure with a high evidence of clinical responses.


Asunto(s)
Antineoplásicos/uso terapéutico , Fiebre , Melanoma/terapia , Perfusión/métodos , Neoplasias Cutáneas/terapia , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Pierna , Metástasis Linfática , Masculino , Melanoma/tratamiento farmacológico , Melanoma/secundario , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Perfusión/efectos adversos , Perfusión/mortalidad , Estudios Retrospectivos , Neoplasias Cutáneas/tratamiento farmacológico , Neoplasias Cutáneas/patología , Resultado del Tratamiento
18.
G Chir ; 18(3): 127-30, 1997 Mar.
Artículo en Italiano | MEDLINE | ID: mdl-9206494

RESUMEN

The performances of totally implantable ports were analyzed in patients with colorectal metastases undergoing intraarterial treatment. Seventy-nine patients received bolus infusion of Cisplatin (DDP, 57 cases) or Epirubicin (EPI, 22 cases) every 21 and 7 days, respectively. Disease progression or toxicity were the most common causes of interruption of treatment, whereas failure of ports occurred in six and two patients out of DDP and EPI groups, respectively. The incidence of single problems for each port was 65% in DDP group and 64% in EPI group, whereas rate of complications for each patient was 30% and 32%, respectively. The 12-months device duration rate in the two groups was 65% (median 17 months) in DDP group and 78% (median 18 months) in EPI group. The implantable ports employed for bolus arterial infusion, allowed adequate treatment periods in most cases, without any difference as far as intervals between cycles is concerned.


Asunto(s)
Antibióticos Antineoplásicos/administración & dosificación , Antineoplásicos/administración & dosificación , Cisplatino/administración & dosificación , Epirrubicina/administración & dosificación , Bombas de Infusión Implantables , Infusiones Intraarteriales/instrumentación , Neoplasias Hepáticas/tratamiento farmacológico , Anciano , Femenino , Humanos , Bombas de Infusión Implantables/efectos adversos , Masculino , Persona de Mediana Edad , Factores de Tiempo
19.
G Chir ; 18(1-2): 7-11, 1997.
Artículo en Italiano | MEDLINE | ID: mdl-9206487

RESUMEN

The influence of timing of surgery in relation to menstrual period on survival of breast cancer patients has been both advanced advocated and disputed. A meta-analysis on published series showed a statistically significant overall odds reduction when surgery is performed in the luteal phase. The records of 165 premenopausal M- breast cancer women, not on hormonal therapies, consecutively operated on from 1977 to 1991 were reviewed. All patients underwent modified radical mastectomies or quadrantectomies plus operative radiotherapy, Node-positive patients received standard adjuvant chemotherapy. Cox regression analysis was used to estimate the relative risk (RR) of death in three models including timing of surgery, age, histology, pathological T and N. In each model, patients were divided into two groups according to the criteria proposed by Badwe, Hrushesky, and Senie. Multivariate analysis showed a significant association between pT and pN and survival, whereas no association with survival was observed for timing of surgery according to Badwe or Hrushesky or Senie criteria (RR = 1.26, RR = 0.91, and RR = 0.88 respectively). Up-to-date agreement on the menstrual phase and relative expected better prognosis is still lacking.


Asunto(s)
Neoplasias de la Mama/cirugía , Carcinoma Ductal de Mama/cirugía , Ciclo Menstrual , Adulto , Neoplasias de la Mama/mortalidad , Neoplasias de la Mama/radioterapia , Carcinoma Ductal de Mama/mortalidad , Carcinoma Ductal de Mama/radioterapia , Fenómenos Cronobiológicos , Terapia Combinada , Femenino , Humanos , Mastectomía Radical Modificada , Mastectomía Segmentaria , Persona de Mediana Edad , Análisis Multivariante , Cuidados Posoperatorios , Premenopausia , Pronóstico , Análisis de Regresión
20.
G Chir ; 18(4): 175-81, 1997 Apr.
Artículo en Italiano | MEDLINE | ID: mdl-9303630

RESUMEN

Several clinical studies have recently suggested that topical or systemic adjuvant hyaluronidase may increase the therapeutic index of anticancer drugs. In cases of disease progression, further objective responses have been observed after the association of hyaluronidase to the previously employed drugs. Some evidences suggest that hyaluronidase improves local diffusion as well as tissue and tumor uptake of the associated drugs. Hence, plasma and tissue concentrations of platinum following administration of cisplatin alone and associated with hyaluronidase have been investigated in 20 rats after intraperitoneal injection and in 10 patients with colorectal liver metastases and local progression of the disease after regional and systemic chemotherapy with intraarterial cisplatin and intravenous 5-fluorouracil. Three out of six refractory patients treated with hepatic intraarterial cisplatin + hyaluronidase showed one minor response and two stable diseases, respectively, without any apparent increase of treatment related toxicity. In turn, adjuvant hyaluronidase increased both the extent distribution and lasting time of cisplatin in the body and reduced plasma levels of total and free platinum originating from cisplatin, without any modification of either unbound fraction of platinum or total body clearance. Hence, adjuvant hyaluronidase seems to increase tissue extraction of cisplatin and, particularly, liver extraction after intraarterial administration in man. These results encourage further studies aimed to determine the clinical role of adjuvant hyaluronidase in patients refractory to regional chemotherapy.


Asunto(s)
Antineoplásicos/administración & dosificación , Carcinoma 256 de Walker/tratamiento farmacológico , Quimioterapia del Cáncer por Perfusión Regional , Cisplatino/administración & dosificación , Cisplatino/farmacocinética , Hialuronoglucosaminidasa/administración & dosificación , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Peritoneales/tratamiento farmacológico , Animales , Antimetabolitos Antineoplásicos/administración & dosificación , Quimioterapia Adyuvante , Cisplatino/sangre , Neoplasias Colorrectales , Fluorouracilo/administración & dosificación , Humanos , Infusiones Intraarteriales , Infusiones Intravenosas , Inyecciones Intraperitoneales , Neoplasias Hepáticas/secundario , Masculino , Ratas , Ratas Sprague-Dawley , Factores de Tiempo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA